These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9493584

  • 21. The effects of age, gene source and familial severity on Factor VIII in normals and haemophilia carriers: analysis by multiple regression.
    Duncan BM, Tunbridge LJ, Lloyd JV.
    Thromb Haemost; 1983 Oct 31; 50(3):722-5. PubMed ID: 6417820
    [Abstract] [Full Text] [Related]

  • 22. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR, Tuller J, Johnson JA.
    Haemophilia; 1999 Mar 31; 5(2):88-95. PubMed ID: 10215955
    [Abstract] [Full Text] [Related]

  • 23. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
    Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M.
    Br J Haematol; 2005 Jan 31; 128(1):100-7. PubMed ID: 15606555
    [Abstract] [Full Text] [Related]

  • 24. Altered serum factor VIII-related antigen (VIII : AGN)/von Willebrand factor (VIII : vWf) in haemophiliacs with inhibitors to factor VIII procoagulant activity (VIII : C).
    Ballard JO, Sanders JC, Eyster ME.
    Thromb Haemost; 1981 Feb 23; 45(1):68-72. PubMed ID: 6166064
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.
    Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP.
    Br J Haematol; 1999 Apr 23; 105(1):110-6. PubMed ID: 10233372
    [Abstract] [Full Text] [Related]

  • 27. Standardisation of factor VIII--V. Calibration of the 2nd International Standard for Factor VIII and von Willebrand factor activities in plasma.
    Heath AB, Barrowcliffe TW.
    Thromb Haemost; 1992 Aug 03; 68(2):155-9. PubMed ID: 1412160
    [Abstract] [Full Text] [Related]

  • 28. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ.
    Thromb Haemost; 2008 Sep 03; 100(3):462-8. PubMed ID: 18766263
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 Sep 03; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

  • 33. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 03; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada.
    Thromb Haemost; 2002 Feb 03; 87(2):224-30. PubMed ID: 11858481
    [Abstract] [Full Text] [Related]

  • 35. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens.
    Morelli VM, de Visser MC, van Tilburg NH, Vos HL, Eikenboom JC, Rosendaal FR, Bertina RM.
    Thromb Haemost; 2007 Apr 03; 97(4):534-41. PubMed ID: 17393014
    [Abstract] [Full Text] [Related]

  • 36. Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?
    Mertens I, Van der Planken M, Corthouts B, Van Gaal LF.
    Metabolism; 2006 May 03; 55(5):650-5. PubMed ID: 16631442
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A, Mathews V, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A.
    Haemophilia; 2008 Jul 03; 14(4):763-7. PubMed ID: 18445014
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.
    Thromb Haemost; 1999 Feb 03; 81(2):229-33. PubMed ID: 10063997
    [Abstract] [Full Text] [Related]

  • 40. Carrier detection in hemophilia A: ABO blood group, multiple measurements, and application of logistic discrimination.
    Percy ME, Rusk AC, Garvey MB, Freedman JJ, Teitel JM, Blake P, Carter C, Andrew M, Johnson M, Inwood M.
    Am J Med Genet; 1988 Dec 03; 31(4):871-9. PubMed ID: 3149148
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.